What's Happening?
Sarepta Therapeutics Inc. is seeking an en banc review by the US Court of Appeals for the Federal Circuit in a patent dispute with RegenxBio Inc. The case centers on the eligibility of a patent covering lab-grown host cells with recombinant DNA, which
Sarepta argues should not be patentable as they involve routine manipulation of natural DNA. The Federal Circuit previously reversed a district court ruling that invalidated the patent, stating that the engineered cells do not occur in nature. This decision has sparked debate over the extent to which Section 101 of the US Patent Act applies to engineered biological materials.
Why It's Important?
The outcome of this case could have significant implications for the biotechnology industry, particularly in how patents for engineered biological materials are evaluated. A ruling in favor of Sarepta could limit the scope of patent eligibility for genetic inventions, potentially affecting innovation and investment in gene therapy and related fields. Conversely, upholding the current decision may provide a clearer framework for patenting engineered DNA, encouraging further development in biotechnology. The case underscores the ongoing tension between protecting intellectual property and ensuring that natural phenomena remain unpatentable.
What's Next?
The Federal Circuit's decision on whether to grant an en banc review will be closely watched by stakeholders in the biotechnology sector. If the review is granted, it could lead to a reevaluation of the criteria for patent eligibility of engineered DNA. The case may also prompt legislative or judicial clarification on the application of Section 101 to biotechnology patents. Companies involved in genetic engineering will need to monitor the outcome to adjust their patent strategies accordingly.
